Open clinical trial data for all? A view from regulators
- PMID: 22505851
- PMCID: PMC3323505
- DOI: 10.1371/journal.pmed.1001202
Open clinical trial data for all? A view from regulators
Abstract
Hans-Georg Eichler from the European Medicines Agency and colleagues provide a view from regulators on access to clinical trial data.
Conflict of interest statement
All authors work for drug regulatory agencies. The authors have declared that no other competing interests exist. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies, or the committees or working parties of the regulatory agencies the authors work for.
Comment on
-
The imperative to share clinical study reports: recommendations from the Tamiflu experience.PLoS Med. 2012;9(4):e1001201. doi: 10.1371/journal.pmed.1001201. Epub 2012 Apr 10. PLoS Med. 2012. PMID: 22505850 Free PMC article.
References
-
- Hrynaszkiewicz I, Altman DG. Towards agreement on best practice for publishing raw clinical trial data. Trials. 2009;10:17. Available: http://www.trialsjournal.com/content/10/1/17. Accessed 9 March 2012. - PMC - PubMed
-
- Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113(2):104–111. - PubMed
-
- Nielsen M. Reinventing discovery: the new era of networked science. Princeton and Oxford: Princeton University Press; 2012.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
